Evolent Health (EVH) Reports In-Line Q1 EPS; Offers FY23 Revenue Guidance
Evolent Health (NYSE: EVH) reported Q1 EPS of $0.20, in-line with the analyst estimate of $0.20. Revenue for the quarter came in at $427.7 million versus the consensus estimate of $434.35 million.
GUIDANCE:
Evolent Health sees FY2023 revenue of $1.94-1.97 billion, versus the consensus of $1.94 billion.
For earnings history and earnings-related data on Evolent Health (EVH) click here.
